October 25, 2007
EntreMed Shows Increased Survival with MKC-1 in Preclinical Renal Cell Cancer ModelOctober 23, 2007
EntreMed Presents Results for Panzem® NCD Phase 2 Ovarian Cancer StudyOctober 16, 2007
EntreMed Appoints Senior Vice President of Research and DevelopmentOctober 04, 2007
EntreMed to Present at the BIO 2007 Investor ForumOctober 02, 2007
EntreMed Receives Deloitte Technology Fast 50 AwardSeptember 27, 2005
Panzem® Demonstrates Safety and Clinical Benefit in Hormone Refractory Prostate CancerSeptember 15, 2005
EntreMed and the National Cancer Institute Commence Research CollaborationAugust 23, 2005
Disease Modifying Activity of 2ME2 Demonstrated in Preclinical Rheumatoid Arthritis StudiesAugust 17, 2005
New Patents Strengthen EntreMed Position in Cancer and InflammationJuly 28, 2005
EntreMed Reports Second Quarter 2005 Financial ResultsJuly 06, 2005
Antitumor Activity Shown for 2ME2 and Analogs in Preclinical Lung Cancer ModelsJune 29, 2005
Duke University Awarded Susan G. Komen Grant to Evaluate EntreMed’s Panzem® NCD in Breast CancerMay 19, 2005
EntreMed to Present at Needham Biotechnology ConferenceMay 03, 2005
EntreMed Reports First Quarter 2005 Financial ResultsApril 27, 2005
EntreMed to Present at Rodman & Renshaw Healthcare ConferencApril 20, 2005
EntreMed Presents Preclinical Data for Second Generation 2ME2 CompoundsApril 20, 2005
EntreMed and Collaborators Present Data for 2ME2 Mechanisms of Action at AACRApril 19, 2005
EntreMed Presents Preclinical Data for Novel PAR-2 Antagonist to Treat Cancer and Inflammatory DiseaApril 14, 2005
EntreMed Granted FDA Orphan Drug Status for Panzem® (2ME2) in Ovarian CancerApril 11, 2005
Disease Modifying Activity of 2ME2 in Rheumatoid Arthritis Validated in Second Preclinical Study
